MusclePharm (MSLPQ) 10-Q 16 Aug 21 2021 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2021	Aug. 11, 2021
Entity Addresses [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	000-53166
Entity Registrant Name	MusclePharm Corporation
Entity Central Index Key	0001415684
Entity Tax Identification Number	77-0664193
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	3753 Howard Hughes Parkway
Entity Address, Address Line Two	Suite 200-849
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89169
City Area Code	800
Local Phone Number	292-3909
Entity Current Reporting Status	No
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		33,479,886
Former Address [Member]
Entity Addresses [Line Items]
Entity Address, Address Line One	4500 Park Granada
Entity Address, Address Line Two	Suite 202
Entity Address, City or Town	Calabasas
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91302

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash	$ 1,016	$ 2,003
Accounts receivable, net of allowances of $1,033 and $3,407 at June 30, 2021 and December 31, 2020, respectively	5,564	7,488
Inventory	1,561	1,032
Prepaid expenses and other current assets	2,182	1,341
Total current assets	10,323	11,864
Property and equipment, net	9	13
Intangible assets, net	195	356
Operating lease right-of-use assets	338	474
Other assets	75	295
TOTAL ASSETS	10,940	13,002
Current liabilities:
Obligation under secured borrowing arrangement	5,297	7,098
Line of credit	2,458	743
Operating lease liability, current	424	381
Convertible note with a related party, net of discount	2,872	2,872
Accounts payable	15,218	13,989
Accrued and other liabilities	6,806	6,924
Total current liabilities	33,075	32,007
Operating lease liability, long-term	119	343
Other long-term liabilities	4,012	5,071
Total liabilities	37,206	37,421
Stockholders’ deficit:
Common stock, par value of $0.001 per share; 100,000,000 shares authorized, 34,261,821 and 33,980,905 shares issued as of June 30, 2021 and December 31, 2020, respectively; 33,386,200 and 33,105,284 shares outstanding as of June 30, 2021 and December 31, 2020, respectively	32	32
Additional paid-in capital	178,569	178,261
Treasury stock, at cost; 875,621 shares	(10,039)	(10,039)
Accumulated deficit	(194,828)	(192,673)
TOTAL STOCKHOLDERS’ DEFICIT	(26,266)	(24,419)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$ 10,940	$ 13,002

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Allowances for doubtful account receivables	$ 1,033	$ 3,407
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	34,261,821	33,980,905
Common stock, shares outstanding	33,386,200	33,105,284
Treasury stock, shares	875,621	875,621

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
Revenue, net	$ 14,908,000	$ 16,993,000	$ 28,029,000	$ 33,224,000
Cost of revenue	12,728,000	12,009,000	22,160,000	23,431,000
Gross profit	2,180,000	4,984,000	5,869,000	9,793,000
Operating expenses:
Advertising and promotion	145,000	188,000	489,000	313,000
Salaries and benefits	1,181,000	1,774,000	2,229,000	3,455,000
Selling, general and administrative	2,115,000	1,807,000	3,512,000	3,718,000
Professional fees	482,000	865,000	1,109,000	1,406,000
Total operating expenses	3,923,000	4,634,000	7,339,000	8,892,000
Loss from operations	(1,743,000)	350,000	(1,470,000)	901,000
Other (expense) income:
Loss on settlement obligation		(37,000)		(87,000)
Interest and other expense, net	(501,000)	(544,000)	(680,000)	(1,083,000)
Loss before provision for income taxes	(2,244,000)	(231,000)	(2,150,000)	(269,000)
Provision for income taxes	7,000	22,000	7,000	44,000
Net loss	$ (2,251,000)	$ (253,000)	$ (2,157,000)	$ (313,000)
Net loss per share, basic and diluted	$ (0.07)	$ (0.01)	$ (0.07)	$ (0.01)
Weighted average shares used to compute net loss per share, basic and diluted	33,386,200	32,764,553	33,131,087	32,612,956

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2019	$ 31	$ 177,914	$ (10,039)	$ (195,858)	$ (27,952)
Balance, shares at Dec. 31, 2019	33,000,412
Stock-based compensation		100			100
Issuance of shares of common stock related to the payment of advertising services		47			47
Issuance of shares of common stock related to the payment of advertising services, shares	101,454
Net loss				(60)	(60)
Balance at Mar. 31, 2020	$ 31	178,061	(10,039)	(195,918)	(27,865)
Balance, shares at Mar. 31, 2020	33,101,866
Balance at Dec. 31, 2019	$ 31	177,914	(10,039)	(195,858)	(27,952)
Balance, shares at Dec. 31, 2019	33,000,412
Net loss					(313)
Balance at Jun. 30, 2020	$ 31	178,209	(10,039)	(196,171)	(27,970)
Balance, shares at Jun. 30, 2020	33,130,039
Balance at Mar. 31, 2020	$ 31	178,061	(10,039)	(195,918)	(27,865)
Balance, shares at Mar. 31, 2020	33,101,866
Stock-based compensation		79			79
Issuance of shares of common stock related to the payment of advertising services		69			69
Issuance of shares of common stock related to the payment of advertising services, shares	28,173
Net loss				(253)	(253)
Balance at Jun. 30, 2020	$ 31	178,209	(10,039)	(196,171)	(27,970)
Balance, shares at Jun. 30, 2020	33,130,039
Balance at Dec. 31, 2020	$ 32	178,261	(10,039)	(192,673)	(24,419)
Balance, shares at Dec. 31, 2020	33,105,284
Stock-based compensation
Stock-based compensation, shares	280,916
Net loss				94	94
Balance at Mar. 31, 2021	$ 32	178,261	(10,039)	(192,579)	(24,325)
Balance, shares at Mar. 31, 2021	33,386,200
Balance at Dec. 31, 2020	$ 32	178,261	(10,039)	(192,673)	(24,419)
Balance, shares at Dec. 31, 2020	33,105,284
Net loss					(2,157)
Balance at Jun. 30, 2021	$ 32	178,569	(10,039)	(194,828)	(26,266)
Balance, shares at Jun. 30, 2021	33,386,200
Balance at Mar. 31, 2021	$ 32	178,261	(10,039)	(192,579)	(24,325)
Balance, shares at Mar. 31, 2021	33,386,200
Stock-based compensation		308			308
Net loss				(2,251)	(2,251)
Balance at Jun. 30, 2021	$ 32	$ 178,569	$ (10,039)	$ (194,828)	$ (26,266)
Balance, shares at Jun. 30, 2021	33,386,200

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,157)	$ (313)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization of property and equipment	6	105
Amortization of intangible assets	160	160
Bad debt expense	326	121
Gain on disposal of property and equipment		(11)
Inventory provision	9	(4)
Stock-based compensation	308	179
Issuance of common stock to non-employees		116
Changes in operating assets and liabilities:
Accounts receivable, net	564	7
Inventory	(538)	(395)
Prepaid expenses and other current assets	192	21
Other assets	355	345
Accounts payable and accrued liabilities	(124)	860
Net cash (used in) provided by operating activities	(899)	1,191
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(3)
Proceeds from disposal of property and equipment		11
Net cash (used in) provided by investing activities	(3)	11
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from line of credit	2,192
Payments on line of credit	(478)	(814)
Proceeds from secured borrowing arrangement, net of reserves	26,211	21,116
Payments on secured borrowing arrangement	(28,011)	(22,639)
Proceeds from issuance of Paycheck Protection Program Loan		965
Repayment of finance lease obligations		(52)
Proceeds of notes payable	186
Repayment of notes payable	(185)	(97)
Net cash used in financing activities	(85)	(1,521)
NET CHANGE IN CASH	(987)	(319)
CASH — BEGINNING OF PERIOD	2,003	1,532
CASH — END OF PERIOD	1,016	1,213
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for taxes	$ 681	$ 402

Description of Business

Description of Business	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Note 1. Description of Business Description of Business MusclePharm Corporation, together with its subsidiaries (the “Company” or “MusclePharm”) is a scientifically-driven, performance lifestyle company that develops, markets and distributes branded sports nutrition products and nutritional supplements that are manufactured by the Company’s co-manufacturers. Our portfolio of recognized brands, including MusclePharm and FitMiss, is marketed and sold globally. The Company has historically incurred significant losses and experienced negative cash flows since inception. As of June 30, 2021, the Company had cash of $ 1.0 million, an increase of $ 0.4 1.0 million from the December 31, 2020 balance of $ 2.0 million. As of June 30, 2021, the Company had a working capital deficit of $ 22.8 million, a stockholders’ deficit of $ 26 .3 million and an accumulated deficit of $ 194.8 million resulting from recurring losses from operations. As a result of our history of losses and financial condition, there is substantial doubt about our ability to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon it generating profits in the future and/or obtaining the necessary financing to meet its obligations and repay liabilities arising from normal business operations when they come due. The Company is evaluating different strategies to obtain financing to fund its operations to cover expenses and focus on achieving a level of revenue adequate to support its current cost structure. Financing strategies may include, but are not limited to, private placements of capital stock, debt borrowings, partnerships and/or collaborations. The Company has been focused on cost containment and improving gross margins by focusing on customers with higher margins, reducing product discounts and promotional activity, along with reducing the number of SKU’s and negotiate pricing for raw materials. In addition, the Company has worked to negotiate lower production costs with its co-manufacturers. Although these steps improved gross margins through the first quarter of 2021, with the recent increases in commodity prices, primarily protein, the company’s gross margins have been impacted and will continue to be impacted unless commodity prices return the same levels that were seen in 2020. In 2021, the Company announced its entrance into the functional energy space with its partnership with a former Rockstar Energy executive. The Company plans to launch 3 new energy products in the summer of 2021. The Company believes with the launch of its new energy products, reductions in operating costs and continued focus on gross profit and top line sales growth will allow it to ultimately achieve sustained profitability. However, the Company can give no assurances that this will occur, especially with the cost to launch new energy products along with the recent increase in the cost of protein, which may have a material impact on the Company’s profitability. Additionally, the Company’s profitability may be materially impacted by the ability of our third-party manufacturers to meet our customers’ demands. Although, the Company believes entering the functional energy space will help to increase sales and gross margin, and reduce exposure to commodity prices, the Company can give no assurances that this will occur. To manage cash flow, the Company has entered into multiple financing arrangements. The Company’s results of operations are affected by economic conditions, including macroeconomic conditions and levels of business confidence. There continues to be significant volatility and economic uncertainty in many markets and the ongoing COVID-19 pandemic contributes to that level of volatility and uncertainty and has created economic disruption. The Company is actively managing its business to respond to the impact. There were no adjustments recorded in the financial statements that might result from the outcome of these uncertainties. The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak, new information which may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time but may have a material impact on our business, financial condition and results of operations. Management continues to monitor the business environment for any significant changes that could impact the Company’s operations. The Company has taken proactive steps to manage costs and discretionary spending, such as remote working and reducing facility related expense.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these statements do not include all the information and notes required by U.S. GAAP for complete financial statements. The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. The Company’s management believes the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for the fair presentation of the Company’s financial position as of June 30, 2021, results of operations for the three and six months ended June 30, 2021 and 2020, and cash flows for the six months ended June 30, 2021 and 2020. The results of operations for the three and six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the year ended December 31, 2021. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 29, 2021. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and accompanying notes. Such estimates include, but are not limited to, allowance for doubtful accounts, revenue discounts and allowances, the valuation of inventory and deferred tax assets, the assessment of useful lives, recoverability and valuation of long-lived assets, likelihood and range of possible losses on contingencies, present value of lease liabilities, among others. Actual results could differ from those estimates. Shipping and handling The Company accounts for shipping and handling costs as fulfillment activities, which are therefore recognized upon shipment of the goods. For the three and six months ended June 30, 2021 the Company incurred $ 0.5 million and $ 1.0 million, respectively, of inbound shipping and handling costs. For the three and six months ended June 30, 2020 the Company incurred $ 0.4 million and $ 0.8 million, respectively, of inbound shipping and handling costs. Shipping and handling costs related to inbound purchases of raw material and finished goods are included in cost of revenue in our consolidated statements of operations. For the three and six months ended June 30, 2021, the Company incurred $ 0.9 1.6 0.6 1.2 Sales discounts and returns The Company excludes from its revenue any amounts collected from customers for sales (and similar) taxes. During the three months ended June 30, 2021 and 2020, the Company recorded discounts, and to a lesser degree, sales returns, totaling $ 1.9 million and $ 3.6 million, respectively, which accounted for 11% and 17% of gross revenue in each period, respectively. During the six months ended June 30, 2021 and 2020, the Company recorded discounts, and to a lesser degree, sales returns, totaling $ 4.4 million and $ 7.6 million, respectively, which accounted for 14% and 19% of gross revenue in each period, respectively. Concentrations Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and accounts receivable. The Company minimizes its credit risk associated with cash by periodically evaluating the credit quality of its primary financial institution. The Company maintains its cash balance at credit-worthy financial institutions that are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $ 250,000 0.8 Significant customers are those that represent more than 10% of the Company’s revenue, net or accounts receivable for each period presented. For the three months ended June 30, 2021, the Company had two customers who individually accounted for 55% and 13% 43% 13% 13% 59% For the three months ended June 30, 2020, the Company had three customers who individually accounted for 30% 24% 21% 33% 23% 16% 31% 18% 16% The Company uses a limited number of non-affiliated suppliers for contract manufacturing of its products. For the three months ended June 30, 2021, the Company had three suppliers who individually accounted for approximately 23% , 15% and 13% of its purchases with contract manufacturers and raw material providers. For the six months ended June 30, 2021, the Company had three suppliers who individually accounted for approximately 24% , 15% and 15% of its purchases with contract manufacturers and raw material providers. Four customers accounted for 33 17 12 11 For the three months ended June 30, 2020, the Company had three suppliers who individually accounted for approximately 33% , 30% and 20% of its purchases with contract manufacturers and raw material providers. For the six months ended June 30, 2020, the Company had three suppliers who individually accounted for approximately 34% , 30% and 17% of its purchases with contract manufacturers and raw material providers. Three customers accounted for 19 12 12 Recent Accounting Pronouncements In July 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In August 2020, the FASB issued ASU No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) The Company is currently evaluating the impact this ASU may have on its consolidated financial statements. In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40) Recently Adopted Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): The Company adopted this ASU effective January 1, 2021, with certain provisions applied retrospectively and other provisions applied prospectively. Adoption of this ASU did not have a material impact to the Company’s condensed consolidated balance sheet, statements of operations, or cash flows. Reclassifications Certain prior period amounts have been reclassified to conform to the current period financial statement presentations, including classification of certain labilities. These changes in presentation did not have a material impact on the Company's financial condition or results of operations.

Inventory

Inventory	6 Months Ended
	Jun. 30, 2021
Inventory Disclosure [Abstract]
Inventory	Note 3. Inventory Inventory consisted solely of finished goods and raw materials used to manufacture our products by one of our co-manufacturers (in thousands): Schedule of Inventory As of June 30, 2021 As of December 31, 2020 Raw materials $ 625 $ 332 Finished goods 936 700 Inventory $ 1,561 $ 1,032

Accrued and Other Liabilities

Accrued and Other Liabilities	6 Months Ended
	Jun. 30, 2021
Payables and Accruals [Abstract]
Accrued and Other Liabilities	Note 4. Accrued and Other Liabilities As of June 30, 2021 and December 31, 2020, the Company’s accrued and other liabilities consisted of the following (in thousands): Schedule of Accrued and Other Liabilities As of June 30, 2021 As of December 31, 2020 Accrued professional fees $ 114 $ 242 Accrued interest 748 644 Accrued payroll and bonus 630 738 Settlements – short-term (Nutrablend and 4Excelsior) 2,949 2,735 Accrued expenses - ThermoLife 1,364 1,364 Accrued and other short-term liabilities 1,001 1,201 Accrued and other liabilities $ 6,806 $ 6,924

Interest and other expense, net

Interest and other expense, net	6 Months Ended
	Jun. 30, 2021
Other Income and Expenses [Abstract]
Interest and other expense, net	Note 5. Interest and other expense, net For the three months ended June 30, 2021 and 2020, “Interest and other expense, net” consisted of the following (in thousands): Schedule of Interest and Other Expense, Net For the Three Months Ended June 30, For the Six Months Ended June 30, 2021 2020 2021 2020 Interest expense, related party $ (147 ) $ (76 ) $ (282 ) $ (152 ) Interest expense, other (235 ) (175 ) (443 ) (332 ) Interest expense, secured borrowing arrangement (258 ) (383 ) (424 ) (748 ) Foreign currency transaction loss 34 16 32 (18 ) Other 105 74 437 167 Total interest and other expense, net $ (501 ) $ (544 ) $ (680 ) $ (1,083 ) “Other” includes sublease income.

Leases

Leases	6 Months Ended
	Jun. 30, 2021
Leases [Abstract]
Leases	Note 6. Leases A summary of the Company’s lease portfolio as of June 30, 2021 and December 31, 2020 is presented in the table below (in thousands): Schedule of Supplemental Balance Sheet Information Balance Sheet Classification June 30, 2021 December 31, 2020 Assets Operating ROU assets, net $ 338 $ 474 Liabilities Current liabilities: Operating Operating lease liability - current $ 424 $ 381 Non-current liabilities: Operating Operating lease liability - long term 119 343 Total lease liabilities $ 543 $ 724 Supplemental cash flow information related to leases was as follows: Schedule of Supplemental Cash Flow Information Six months ended June 30, 2021 Six months ended June 30, 2020 Cash paid for amounts included in the measurement of lease liabilities (in thousands): Operating cash flows from operating leases $ 180 $ 397 Operating cash flows from finance leases — 1 Financing cash flows from finance leases — 52 The weighted average remaining lease term was as follows: Operating leases (in years) 1.2 2.0 Finance leases (in years) — 0.1 The weighted average discount rate was as follows: Operating leases 18 % 18 % Finance leases — 5 %

Other Long-Term Liabilities

Other Long-Term Liabilities	6 Months Ended
	Jun. 30, 2021
Other Liabilities Disclosure [Abstract]
Other Long-Term Liabilities	Note 7. Other Long-Term Liabilities As of June 30, 2021, and December 31, 2020, the Company’s other long-term liabilities consisted of the following (in thousands): Schedule of Other Long-Term Liabilities As of June 30, 2021 As of December 31, 2020 Settlements – long-term (Nutrablend and 4Excelsior) 3,143 3,906 Paycheck Protection Program loan 643 965 Other — 200 Other long-term debt $ 3,786 $ 5,071

Debt

Debt	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Debt	Note 8. Debt Related-Party Refinanced Convertible Note On November 29, 2020, the Company entered into a refinancing agreement with Mr. Ryan Drexler, the Company’s Chairman of the Board of Directors and Chief Executive Officer (the “November 2020 Refinancing”), in which the Company issued to Mr. Drexler a convertible secured promissory note (the “November 2020 Convertible Note”) in the original principal amount of $ 2,871,967 2.9 12% Mr. Drexler may, at any time, and from time to time, upon written notice to the Company, convert the outstanding principal and accrued interest into shares of Common Stock, at a conversion price of $ 0.23 0.10 The November 2020 Convertible Note contains customary restrictions on the ability of the Company to, among other things, grant liens or incur indebtedness other than certain obligations incurred in the ordinary course of business. The restrictions are also subject to certain additional qualifications and carveouts, as set forth in the November 2020 Convertible Note. The November 2020 Convertible Note is subordinated to the secured borrowing arrangement the Company entered into with Prestige Capital Corporation (“Prestige”). For the three months ended June 30, 2021 and 2020, interest expense related to the related party convertible secured promissory note was $ 0.1 0.1 For the six months ended June 30, 2021 and 2020, interest expense related to the related party convertible secured promissory note was $ 0.2 0.2 Related-Party Secured Revolving Promissory Note On October 15, 2020, the Company entered into a secured revolving promissory note (the “Revolving Note”) with Ryan Drexler. Under the terms of the Revolving Note, the Company can borrow up to $ 3.0 12% As of June 30, 2021, the outstanding balance on the revolving note was $ 2.5 0.1 0.1 Secured Borrowing Arrangement In January 2016, the Company entered into a Purchase and Sale Agreement (the “Purchase and Sale Agreement”) with Prestige, pursuant to which the Company agreed to sell and assign and Prestige agreed to buy and accept, certain accounts receivable owed to the Company (“Accounts”). Under the terms of the Purchase and Sale Agreement, upon the receipt and acceptance of each assignment of Accounts, Prestige will pay the Company 80% 12.5 20% 0.7% 4% with the exception of international and certain domestic customers On April 10, 2019, the Company and Prestige amended the terms of the agreement. The agreement was extended until April 1, 2020 On June 14, 2021, Prestige advanced the Company $ 1 six 15% 2% As of June 30, 2021, and December 31, 2020, the Company had outstanding borrowings under the secured borrowing arrangement of approximately $ 5.3 7.1 During the three months ended June 30, 2021 and 2020, the Company assigned to Prestige, accounts with an aggregate face amount of approximately $ 18.5 million and $ 14.8 million, respectively, for which Prestige paid to the Company approximately $ 14.7 million and $ 11.7 million, respectively, in cash. During the three months ended June 30, 2021 and 2020, $ 14.2 million and $ 12.6 million, respectively, was repaid to Prestige, including fees and interest. During the six months ended June 30, 2021 and 2020, the Company assigned to Prestige, accounts with an aggregate face amount of approximately $ 32.8 26.4 26.2 21.1 28.0 22.6 Paycheck Protection Program Loan Due to economic uncertainty as a result of the ongoing pandemic (COVID-19), on May 14, 2020, the Company received an aggregate principal amount of $ 964,910 1% The Note is expected to mature on May 16, 2025 As of June 30, 2021, the Company owed approximately $ 1.0 million (principal plus accrued interest), which $ 0.1

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 9. Commitments and Contingencies Settlements Manchester City Football Group The Company was engaged in a dispute with City Football Group Limited (“CFG”), the owner of Manchester City Football Group, concerning amounts allegedly owed by the Company under a sponsorship agreement with CFG (the “Sponsorship Agreement”). In August 2016, CFG commenced arbitration in the United Kingdom against the Company, seeking approximately $ 8.3 On July 28, 2017, the Company approved a Settlement Agreement (the “CFG Settlement Agreement”) with CFG effective July 7, 2017. The CFG Settlement Agreement represents a full and final settlement of all litigation between the parties. Under the terms of the agreement, the Company agreed to pay CFG a sum of $ 3 1 1 1 0.3 During the three months ended June 30, 2021 and 2020, the Company recorded a charge of $ 19,000 19,000 38,000 38,000 Nutrablend Matter On February 27, 2020, Nutrablend, a manufacturer of MusclePharm products, filed an action against the Company in the United States District Court for the Eastern District of California, claiming approximately $ 3.1 On September 25, 2020, the parties successfully mediated the case to a settlement (the “Nutrablend Agreement”) and the Company agreed to (i) pay approximately $ 3.1 The Company agreed to issue Purchase Orders in a combined total amount of at least (i) $ 1,500,000 1,800,000 2,100,000 2,100,000 1,400,000 700,000 2.0 3.0 On July 7, 2021, the Company commenced an action against Nutrablend in the Central District of California, seeking (i) a declaration that the Nutrablend Agreement purchase order provisions have been terminated due to Nutrablend’s failure to provide the Company with reasonable assurances of its ability to fulfill its purchase orders; (ii) a declaration that approximately $ 2.0 The Company determined that approximately $ 1.1 1.0 0.7 During the three and six months ended June 30, 2021 the Company recorded interest of $ 0.1 0.1 4Excelsior Matter On March 18, 2019, Excelsior Nutrition, Inc. (“4Excelsior”), a manufacturer of MusclePharm products, filed an action against the Company in the Superior Court of the State of California for the County of Los Angeles, claiming approximately $ 6.2 7.8 On December 16, 2020, the Company and 4Excelsior entered into a Settlement Agreement and Mutual Release (“the Agreement”), pursuant to which the parties resolved and settled the civil action pending in the Superior Court of the State of California for the County of Los Angeles (the “Litigation”). The parties agreed to a mutual general release of claims and to jointly file within 10 business days of the effective date of the Agreement a stipulation and proposed order of dismissal, dismissing with prejudice all claims and counterclaims asserted in the Litigation. The Company agreed to pay $ 4.75 70,000 0.1 18% The Company determined that approximately $ 1.1 2.2 0.8 During the three and six months ended June 30, 2021, the Company recorded interest expense of $ 0.1 0.2 Contingencies In the normal course of business or otherwise, the Company may become involved in legal proceedings. The Company will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. The accrual for a litigation loss contingency might include, for example, estimates of potential damages, outside legal fees and other directly related costs expected to be incurred. The Company provides disclosures for material contingencies when there is a reasonable possibility that a loss or an additional loss may be incurred. In assessing whether a loss is a reasonable possibility, the Company may consider the following factors, among others: the nature of the litigation, claim or assessment, available information, opinions or views of legal counsel and other advisors, and the experience gained from similar cases. As of June 30, 2021, the Company was involved in the following material legal proceedings described below. ThermoLife International In January 2016, ThermoLife International LLC (“ThermoLife”), a supplier of nitrates to the Company, filed a complaint against the Company in Arizona state court. ThermoLife alleged that the Company failed to meet minimum purchase requirements contained in the parties’ supply agreement. The court held a bench trial on the issue of damages in October 2019, and on December 4, 2019, the court entered judgment in favor of ThermoLife and against the Company in the amount of $ 1.6 0.9 0.3 0.4 1.6 1.8 0.6 0.25 0.35 12,500 0.3 1.8 For both the three months ended June 30, 2021 and 2020, interest expense recognized by the Company on the awarded damages was $ 22,000 and for both the six months ended June 30, 2021 and 2020, interest expense recognized by the Company on the awarded damages was $ 44,000 . The Company intends to vigorously continue pursuing its defenses. On June 25, 2021, the Company filed a petition for review in the Arizona Supreme Court requesting that the Court accept review of the appeal affirming the judgment against the Company. ThermoLife opposed the petition for review on July 26, 2021. The Arizona Supreme Court has not yet ruled on the Company’s petition for review. White Winston Select Asset Fund Series MP-18, LLC et al., v. MusclePharm Corp., et al., (Nev. Dist. Ct.; Cal. Superior Court; Colorado Dist. Ct.; Mass. Super. Ct.) On August 21, 2018, White Winston Select Asset Fund Series MP-18, LLC and White Winston Select Asset Fund, LLC (together “White Winston”) initiated a derivative action against the Company and its directors (the “director defendants”). White Winston alleges that the director defendants breached their fiduciary duties by improperly approving the refinancing of three promissory notes issued by the Company to Mr. Drexler (the “Amended Note”) in exchange for $ 18.0 Along with its complaint, White Winston also filed a motion for a temporary restraining order (“TRO”) and preliminary injunction enjoining the exercise of Mr. Drexler’s conversion right under the Amended Note. On August 23, 2018, the Nevada district court issued an ex parte TRO. On September 14, 2018, the court let the TRO expire and denied White Winston’s request for a preliminary injunction, finding, among other things, that White Winston did not show a likelihood of success on the merits of the underlying action and failed to establish irreparable harm. Following the court’s decision, the Company filed a motion seeking to recoup the legal fees and costs it incurred in responding to the preliminary injunction motion. On October 31, 2019, the court awarded the Company $ 56,000 Due to the uncertainty associated with determining our liability, if any, and due to our inability to ascertain with any reasonable degree of likelihood, as of the date of this report, the outcome of the trial, the Company has not recorded an estimate for its potential liability. On June 17, 2019, White Winston moved for the appointment of a temporary receiver over the Company, citing Plante Moran’s resignation. The court granted White Winston’s request to hold an evidentiary hearing on the motion, but subsequently stayed the action pending the parties’ attempts to resolve their dispute. Although the parties have been unable to reach a resolution, the litigation has not yet resumed. On July 30, 2019, White Winston filed an action in the Superior Court of the State of California in and for the County of Los Angeles, seeking access to the Company’s books and records and requesting the appointment of an independent auditor for the company. On February 25, 2021, the court ordered the Company to produce certain documents, denied White Winston’s request for an auditor, and ordered the Company to pay a $ 1,500 92,942 IRS Audit On April 6, 2016, the Internal Revenue Service (“IRS”) selected our 2014 Federal Income Tax Return for audit. As a result of the audit, the IRS proposed certain adjustments with respect to the tax reporting of our former executives’ 2014 restricted stock grants. Due to the Company’s current and historical loss position, the proposed adjustments would have no material impact on the Company’s Federal income tax. On October 5, 2016, the IRS commenced an audit of our employment and withholding tax liability for 2014. The IRS contended that the Company inaccurately reported the value of the restricted stock grants and improperly failed to provide for employment taxes and Federal tax withholding on these grants. In addition, the IRS proposed certain penalties associated with the Company’s filings. On April 4, 2017, the Company received a “30-day letter” from the IRS asserting back taxes and penalties of approximately $ 5.3 4.4 0.9 2.0 The Company’s counsel submitted a formal protest to the IRS disputing on several grounds all of the proposed adjustments and penalties on the Company’s behalf, and the Company pursued this matter vigorously through the IRS appeal process. An Appeals Conference was held with the IRS in Denver, Colorado on July 31, 2019. At the conference, the Company made substantial arguments challenging the IRS’s claims for employment taxes and penalties. On December 16, 2019, a further Appeals Conference was held with the IRS by telephone. At the telephone conference, the Appeals Officer confirmed that he agreed with the Company’s argument that the failure to deposit penalties should be conceded by the IRS. The failure to deposit penalties total about $ 2 7.3 5.3 The remaining issue involved the fair market value of restricted stock units the Company granted to certain former officers (the “Former Officers”) of the Company under Internal Revenue Code § 83. The Company and the IRS disagreed as to the value of the restricted stock on the date of the grants, i.e., October 1, 2014. The Company and the IRS exchanged expert valuation reports on the fair market value of the stock and had extensive negotiations on this issue. The IRS also made parallel claims regarding the restricted stock units against the Former Officers of the Company. The IRS asserted that the Former Officers received ordinary income from the stock grants, and that they owe additional personal income taxes based on the fair market value of the stock. The Former Officers’ cases, unlike the Company’s case, are pending before the United States Tax Court. In the Tax Court litigation, the Former Officers are challenging the IRS’s determinations regarding the fair market value of the restricted stock grants on October 1, 2014. The Former Officers have separate counsel from the Company. The same IRS Appeals Officer and Revenue Agents assigned to the Company’s case are also involved in the cases for the Former Officers. Throughout the proceedings, the Company has argued to the IRS that it is the Former Officers who are directly and principally liable for the amount of any tax due, and not the Company. The Former Officers cases were scheduled for trial in Tax Court on March 9, 2020. The trial of the cases was continued by the Court on February 4, 2020. The basis for the continuance was that the IRS and the Former Officers had made progress toward a settlement of the valuation issue involving the grants of the restricted stock. The Tax Court ordered the Former Officers to file status reports regarding progress of their settlement negotiations with the IRS on or before February 28, 2021. The IRS and the Former Officers filed status reports with the Tax Court on February 26, 2021. After receiving the status reports, the Tax Court issued an order directing the parties to file further status reports on or before July 9, 2021. The Tax Court has not set a trial dates in the cases of the Former Officers. On June 2, 2021, the IRS confirmed to the Company that the statutes of limitations for the assessment and collection of employment tax and corporation income tax against the Company expired on December 15, 2020, without any assessments of tax or penalties. The IRS has told the Company that the employment tax and corporation income tax cases against the Company have been closed with finality, and that the Company has no liability for employment tax and corporation income tax for 2014. On August 22, 2018, Richard Estalella filed an action against us and two other defendants in the Colorado District Court for the County of Denver, seeking damages arising out of the IRS’s assertion of tax liability and penalties relating to the 2014 restricted stock grants. We have answered Estalella’s complaint, asserted counterclaims against Estalella for his failure to ensure that all withholding taxes were paid in connection with the 2014 restricted stock grants, and filed cross-claims against two valuation firms named in the action (as well as their principals) for failing to properly value the 2014 restricted stock grants for tax purposes. Trial in the matter has been scheduled for February 7, 2022. There are no amounts accrued related to this matter and the Company will continue to vigorously litigate the matter.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Note 10. Stock-Based Compensation Restricted Stock For the three and six months ended June 30, 2021, the Company granted 25,000 29,000 There were no For the three and six months ended June 30, 2021, the Company recorded $ 0.0 For the three and six months ended June 30, 2020, the Company recorded $ 0.1 0.2 Transaction Equity Bonus On April 5, 2021, with the appointment of the Company’s President and Chief Financial Officer, the Company granted an award where upon the occurrence of a sale of the Company, the President and Chief Financial Officer will receive 2% 1.0 For the three and six months ended June 30, 2021, the Company recorded $ 0.2 For the three and six months ended June 30, 2020, the Company recorded no Stock Options On May 12, 2021, the Company entered into an Agreement (the “Agreement”) with Joseph Cannata (“Cannata”), pursuant to which the Company has engaged Cannata on a non-exclusive basis to assist with the growth of the Company’s energy beverage product line. In connection with entry into the Agreement, the Company issued to Cannata an option to purchase 1,673,994 1.12 10 1.9 7.5 205% 1.34% 0% For the three and six months ended June 30, 2021, the Company recorded approximately $ 60,000 For the three and six months ended June 30, 2020, the Company recorded no

Net Loss per Share

Net Loss per Share	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
Net Loss per Share	Note 11. Net Loss per Share Basic net loss per share is computed by dividing net loss for the period by the weighted average number of shares of common stock outstanding during each period. The following table sets forth the computation of the Company’s basic and diluted net loss per share for the periods presented (in thousands, except share and per share data): Schedule of Basic and Diluted Net Income (loss) Per Share For the Three Months Ended June 30, For the Six Months Ended June 30, 2021 2020 2021 2020 Net loss $ (2,251 ) $ (253 ) $ (2,157 ) $ (313 ) Weighted average common shares used in computing net loss per share, basic and diluted 33,386,200 32,764,553 33,131,087 32,612,956 Net loss per share, basic and diluted $ (0.07 ) $ (0.01 ) $ (0.07 ) $ (0.01 ) Diluted net loss per share is computed by dividing net loss for the period by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during each period. The Company uses the treasury stock method to determine whether there is a dilutive effect of outstanding potentially dilutive securities, and the if-converted method to assess the dilutive effect of the convertible notes. There was no dilutive effect for the outstanding awards for the three and six months ended June 30, 2021 and 2020, as the Company reported net loss for all periods presented. However, if the Company had net income for the three and six months ended June 30, 2021, the potentially dilutive securities included in earnings per share computation would have been 12,544,774 2,663,715 Total outstanding potentially dilutive securities were comprised of the following: Schedule of Outstanding Potentially Dilutive Securities As of June 30, 2021 2020 Stock options 171,703 171,703 Warrants — 1,289,378 Unvested restricted stock — 270,660 Convertible notes 12,373,071 931,974 Total common stock equivalents 12,544,774 2,663,715

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Note 12. Income Taxes The Company recorded a tax provision of $ 7,000 and $ 22,000 for the three months ended June 30, 2021 and 2020, respectively, and $ 7,000 and $ 44,000 for the six months ended June 30, 2021 and 2020, respectively. Income taxes are provided for the tax effects of transactions reported in the consolidated financial statements and consist of taxes currently due. Deferred taxes relate to differences between the basis of assets and liabilities for financial and income tax reporting which will be either taxable or deductible when the assets or liabilities are recovered or settled. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred income tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based on consideration of these items, management has determined that enough uncertainty exists relative to the realization of the deferred income tax asset balances to warrant the application of a full valuation allowance as of June 30, 2021.

Segments, Geographical Informat

Segments, Geographical Information	6 Months Ended
	Jun. 30, 2021
Segment Reporting [Abstract]
Segments, Geographical Information	Note 13. Segments, Geographical Information The Company’s chief operating decision maker reviews financial information presented on a consolidated basis for purposes of allocating resources and evaluating financial performance. As such, the Company currently has a single reporting segment and operating unit structure. In addition, substantially all long-lived assets are attributable to operations in the U.S. for both periods presented. Revenue, net by geography is based on the company addresses of the customers. The following table sets forth revenue, net by geographic area (in thousands): Schedule of Revenue, Net by Geographic Area For the Three Months Ended June 30, For the Six Months Ended June 30, 2021 2020 2021 2020 Revenue, net: United States $ 9,050 $ 13,514 $ 18,562 $ 25,361 International 5,858 3,479 9,467 7,863 Total revenue, net $ 14,908 $ 16,993 $ 28,029 $ 33,224 The MusclePharm brands are marketed across major global retail distribution channels. Below is a table of revenue, net by our major distribution channel (in thousands): Schedule of Revenue, Net by Major Distribution Channel For the Three Months Ended June 30, 2021 % of 2020 % of Distribution Channel Specialty $ 9,983 67 % $ 8,933 53 % International 1,775 12 % 3,479 20 % FDM 3,150 21 % 4,581 27 % Total $ 14,908 100 % $ 16,993 100 % For the Six Months Ended June 30, 2021 % of 2020 % of Distribution Channel Specialty $ 17,055 61 % $ 16,969 51 % International 6,148 22 % 7,863 24 % FDM 4,826 17 % 8,392 25 % Total $ 28,029 100 % $ 33,224 100 %

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 14. Subsequent Events Related-Party Refinanced Convertible Note On August 13, 2021 the Company and Ryan Drexler agreed to extend the November 2020 Convertible Note through July 14, 2022. The amendment did not change any terms of the agreement other than the maturity date. Related Party Secured Revolving Promissory Note On August 13, 2021, the Company issued to Ryan Drexler (the “Holder”) a convertible secured promissory note (the “August 2021 Convertible Note”) in the original principal amount of $ 2,457,549 The August 2021 Convertible Note bears interest at the rate of 12% At the Company’s option (as determined by its independent directors), the Company may repay up to one sixth of any interest payment by either adding such amount to the principal amount of the August 2021 Convertible Note or by converting such interest amount into an equivalent amount of the Company’s common stock, $ 0.001 July 14, 2022 The Holder may, at any time, and from time to time, upon written notice to the Company, convert the outstanding principal and accrued interest into shares of Common Stock, at a conversion price equal to the closing price of the common stock on October 15, 2021. The Company may prepay the August 2021 Convertible Note by giving the Holder between 15 and 60 days’ notice depending upon the specific circumstances, subject to the Holder’s conversion right. The August 2021 Convertible Note contains customary events of default, including, among others, the failure by the Company to make a payment of principal or interest when due. Following an event of default, at the option of the Holder and upon written notice to the Company, or automatically under certain circumstances, all outstanding principal and accrued interest will become due and payable. The August 2021 Convertible Note also contains customary restrictions on the ability of the Company to, among other things, grant liens or incur indebtedness other than certain obligations incurred in the ordinary course of business. The restrictions are also subject to certain additional qualifications and carveouts, as set forth in the August 2021 Convertible Note. The August 2021 Convertible Note is subordinated to certain other indebtedness of the Company. Secured Borrowing Arrangement On July 26, 2021, Prestige advanced the Company $ 1 six 15% 1 18,750

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these statements do not include all the information and notes required by U.S. GAAP for complete financial statements. The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. The Company’s management believes the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for the fair presentation of the Company’s financial position as of June 30, 2021, results of operations for the three and six months ended June 30, 2021 and 2020, and cash flows for the six months ended June 30, 2021 and 2020. The results of operations for the three and six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the year ended December 31, 2021. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 29, 2021.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and accompanying notes. Such estimates include, but are not limited to, allowance for doubtful accounts, revenue discounts and allowances, the valuation of inventory and deferred tax assets, the assessment of useful lives, recoverability and valuation of long-lived assets, likelihood and range of possible losses on contingencies, present value of lease liabilities, among others. Actual results could differ from those estimates.
Shipping and handling	Shipping and handling The Company accounts for shipping and handling costs as fulfillment activities, which are therefore recognized upon shipment of the goods. For the three and six months ended June 30, 2021 the Company incurred $ 0.5 million and $ 1.0 million, respectively, of inbound shipping and handling costs. For the three and six months ended June 30, 2020 the Company incurred $ 0.4 million and $ 0.8 million, respectively, of inbound shipping and handling costs. Shipping and handling costs related to inbound purchases of raw material and finished goods are included in cost of revenue in our consolidated statements of operations. For the three and six months ended June 30, 2021, the Company incurred $ 0.9 1.6 0.6 1.2
Sales discounts and returns	Sales discounts and returns The Company excludes from its revenue any amounts collected from customers for sales (and similar) taxes. During the three months ended June 30, 2021 and 2020, the Company recorded discounts, and to a lesser degree, sales returns, totaling $ 1.9 million and $ 3.6 million, respectively, which accounted for 11% and 17% of gross revenue in each period, respectively. During the six months ended June 30, 2021 and 2020, the Company recorded discounts, and to a lesser degree, sales returns, totaling $ 4.4 million and $ 7.6 million, respectively, which accounted for 14% and 19% of gross revenue in each period, respectively.
Concentrations	Concentrations Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and accounts receivable. The Company minimizes its credit risk associated with cash by periodically evaluating the credit quality of its primary financial institution. The Company maintains its cash balance at credit-worthy financial institutions that are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $ 250,000 0.8 Significant customers are those that represent more than 10% of the Company’s revenue, net or accounts receivable for each period presented. For the three months ended June 30, 2021, the Company had two customers who individually accounted for 55% and 13% 43% 13% 13% 59% For the three months ended June 30, 2020, the Company had three customers who individually accounted for 30% 24% 21% 33% 23% 16% 31% 18% 16% The Company uses a limited number of non-affiliated suppliers for contract manufacturing of its products. For the three months ended June 30, 2021, the Company had three suppliers who individually accounted for approximately 23% , 15% and 13% of its purchases with contract manufacturers and raw material providers. For the six months ended June 30, 2021, the Company had three suppliers who individually accounted for approximately 24% , 15% and 15% of its purchases with contract manufacturers and raw material providers. Four customers accounted for 33 17 12 11 For the three months ended June 30, 2020, the Company had three suppliers who individually accounted for approximately 33% , 30% and 20% of its purchases with contract manufacturers and raw material providers. For the six months ended June 30, 2020, the Company had three suppliers who individually accounted for approximately 34% , 30% and 17% of its purchases with contract manufacturers and raw material providers. Three customers accounted for 19 12 12
Recent Accounting Pronouncements	Recent Accounting Pronouncements In July 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In August 2020, the FASB issued ASU No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) The Company is currently evaluating the impact this ASU may have on its consolidated financial statements. In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40)
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): The Company adopted this ASU effective January 1, 2021, with certain provisions applied retrospectively and other provisions applied prospectively. Adoption of this ASU did not have a material impact to the Company’s condensed consolidated balance sheet, statements of operations, or cash flows.
Reclassifications	Reclassifications Certain prior period amounts have been reclassified to conform to the current period financial statement presentations, including classification of certain labilities. These changes in presentation did not have a material impact on the Company's financial condition or results of operations.

Inventory (Tables)

Inventory (Tables)	6 Months Ended
	Jun. 30, 2021
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory consisted solely of finished goods and raw materials used to manufacture our products by one of our co-manufacturers (in thousands): Schedule of Inventory As of June 30, 2021 As of December 31, 2020 Raw materials $ 625 $ 332 Finished goods 936 700 Inventory $ 1,561 $ 1,032

Accrued and Other Liabilities (

Accrued and Other Liabilities (Tables)	6 Months Ended
	Jun. 30, 2021
Payables and Accruals [Abstract]
Schedule of Accrued and Other Liabilities	As of June 30, 2021 and December 31, 2020, the Company’s accrued and other liabilities consisted of the following (in thousands): Schedule of Accrued and Other Liabilities As of June 30, 2021 As of December 31, 2020 Accrued professional fees $ 114 $ 242 Accrued interest 748 644 Accrued payroll and bonus 630 738 Settlements – short-term (Nutrablend and 4Excelsior) 2,949 2,735 Accrued expenses - ThermoLife 1,364 1,364 Accrued and other short-term liabilities 1,001 1,201 Accrued and other liabilities $ 6,806 $ 6,924

Interest and other expense, n_2

Interest and other expense, net (Tables)	6 Months Ended
	Jun. 30, 2021
Other Income and Expenses [Abstract]
Schedule of Interest and Other Expense, Net	For the three months ended June 30, 2021 and 2020, “Interest and other expense, net” consisted of the following (in thousands): Schedule of Interest and Other Expense, Net For the Three Months Ended June 30, For the Six Months Ended June 30, 2021 2020 2021 2020 Interest expense, related party $ (147 ) $ (76 ) $ (282 ) $ (152 ) Interest expense, other (235 ) (175 ) (443 ) (332 ) Interest expense, secured borrowing arrangement (258 ) (383 ) (424 ) (748 ) Foreign currency transaction loss 34 16 32 (18 ) Other 105 74 437 167 Total interest and other expense, net $ (501 ) $ (544 ) $ (680 ) $ (1,083 )

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2021
Leases [Abstract]
Schedule of Supplemental Balance Sheet Information	A summary of the Company’s lease portfolio as of June 30, 2021 and December 31, 2020 is presented in the table below (in thousands): Schedule of Supplemental Balance Sheet Information Balance Sheet Classification June 30, 2021 December 31, 2020 Assets Operating ROU assets, net $ 338 $ 474 Liabilities Current liabilities: Operating Operating lease liability - current $ 424 $ 381 Non-current liabilities: Operating Operating lease liability - long term 119 343 Total lease liabilities $ 543 $ 724
Schedule of Supplemental Cash Flow Information	Supplemental cash flow information related to leases was as follows: Schedule of Supplemental Cash Flow Information Six months ended June 30, 2021 Six months ended June 30, 2020 Cash paid for amounts included in the measurement of lease liabilities (in thousands): Operating cash flows from operating leases $ 180 $ 397 Operating cash flows from finance leases — 1 Financing cash flows from finance leases — 52 The weighted average remaining lease term was as follows: Operating leases (in years) 1.2 2.0 Finance leases (in years) — 0.1 The weighted average discount rate was as follows: Operating leases 18 % 18 % Finance leases — 5 %

Other Long-Term Liabilities (Ta

Other Long-Term Liabilities (Tables)	6 Months Ended
	Jun. 30, 2021
Other Liabilities Disclosure [Abstract]
Schedule of Other Long-Term Liabilities	As of June 30, 2021, and December 31, 2020, the Company’s other long-term liabilities consisted of the following (in thousands): Schedule of Other Long-Term Liabilities As of June 30, 2021 As of December 31, 2020 Settlements – long-term (Nutrablend and 4Excelsior) 3,143 3,906 Paycheck Protection Program loan 643 965 Other — 200 Other long-term debt $ 3,786 $ 5,071

Net Loss per Share (Tables)

Net Loss per Share (Tables)	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Income (loss) Per Share	The following table sets forth the computation of the Company’s basic and diluted net loss per share for the periods presented (in thousands, except share and per share data): Schedule of Basic and Diluted Net Income (loss) Per Share For the Three Months Ended June 30, For the Six Months Ended June 30, 2021 2020 2021 2020 Net loss $ (2,251 ) $ (253 ) $ (2,157 ) $ (313 ) Weighted average common shares used in computing net loss per share, basic and diluted 33,386,200 32,764,553 33,131,087 32,612,956 Net loss per share, basic and diluted $ (0.07 ) $ (0.01 ) $ (0.07 ) $ (0.01 )
Schedule of Outstanding Potentially Dilutive Securities	Total outstanding potentially dilutive securities were comprised of the following: Schedule of Outstanding Potentially Dilutive Securities As of June 30, 2021 2020 Stock options 171,703 171,703 Warrants — 1,289,378 Unvested restricted stock — 270,660 Convertible notes 12,373,071 931,974 Total common stock equivalents 12,544,774 2,663,715

Segments, Geographical Inform_2

Segments, Geographical Information (Tables)	6 Months Ended
	Jun. 30, 2021
Segment Reporting [Abstract]
Schedule of Revenue, Net by Geographic Area	Revenue, net by geography is based on the company addresses of the customers. The following table sets forth revenue, net by geographic area (in thousands): Schedule of Revenue, Net by Geographic Area For the Three Months Ended June 30, For the Six Months Ended June 30, 2021 2020 2021 2020 Revenue, net: United States $ 9,050 $ 13,514 $ 18,562 $ 25,361 International 5,858 3,479 9,467 7,863 Total revenue, net $ 14,908 $ 16,993 $ 28,029 $ 33,224
Schedule of Revenue, Net by Major Distribution Channel	The MusclePharm brands are marketed across major global retail distribution channels. Below is a table of revenue, net by our major distribution channel (in thousands): Schedule of Revenue, Net by Major Distribution Channel For the Three Months Ended June 30, 2021 % of 2020 % of Distribution Channel Specialty $ 9,983 67 % $ 8,933 53 % International 1,775 12 % 3,479 20 % FDM 3,150 21 % 4,581 27 % Total $ 14,908 100 % $ 16,993 100 % For the Six Months Ended June 30, 2021 % of 2020 % of Distribution Channel Specialty $ 17,055 61 % $ 16,969 51 % International 6,148 22 % 7,863 24 % FDM 4,826 17 % 8,392 25 % Total $ 28,029 100 % $ 33,224 100 %

Description of Business (Detail

Description of Business (Details Narrative) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and Cash Equivalents, at Carrying Value	$ 1,016	$ 1,016		$ 2,003
Cash, Period Increase (Decrease)	400	1,000
Working capital deficit	22,800	22,800
Stockholders' Equity Attributable to Parent	26,266	26,266	$ 24,325	24,419	$ 27,970	$ 27,865	$ 27,952
Retained Earnings (Accumulated Deficit)	$ 194,828	$ 194,828		$ 192,673

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Product Information [Line Items]
Sales returns and discounts	$ 1,900,000	$ 3,600,000	$ 4,400,000	$ 7,600,000
Sales returns and discounts as a percentage of sales	11.00%	17.00%	14.00%	19.00%
Uninsured cash balance	$ 800,000		$ 800,000
Revenue from Contract with Customer Benchmark [Member] | Customer Concentration Risk [Member] | Customer One [Member]
Product Information [Line Items]
Concentration Risk, Percentage	55.00%	30.00%	43.00%	33.00%
Revenue from Contract with Customer Benchmark [Member] | Customer Concentration Risk [Member] | Customer One [Member]
Product Information [Line Items]
Concentration Risk, Percentage	13.00%	24.00%	13.00%	23.00%
Revenue from Contract with Customer Benchmark [Member] | Customer Concentration Risk [Member] | Customer Three [Member]
Product Information [Line Items]
Concentration Risk, Percentage		21.00%	13.00%	16.00%
Revenue from Contract with Customer Benchmark [Member] | Supplier Concentration Risk [Member] | Supplier One [Member]
Product Information [Line Items]
Concentration Risk, Percentage	23.00%	33.00%	24.00%	34.00%
Revenue from Contract with Customer Benchmark [Member] | Supplier Concentration Risk [Member] | Supplier Two [Member]
Product Information [Line Items]
Concentration Risk, Percentage	15.00%	30.00%	15.00%	30.00%
Revenue from Contract with Customer Benchmark [Member] | Supplier Concentration Risk [Member] | Supplier Three [Member]
Product Information [Line Items]
Concentration Risk, Percentage	13.00%	20.00%	15.00%	17.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer One [Member]
Product Information [Line Items]
Concentration Risk, Percentage			59.00%	31.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer One [Member]
Product Information [Line Items]
Concentration Risk, Percentage				18.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer Three [Member]
Product Information [Line Items]
Concentration Risk, Percentage				16.00%
Account Payables [Member] | Customer Concentration Risk [Member] | Customer One [Member]
Product Information [Line Items]
Concentration Risk, Percentage			33.00%	19.00%
Account Payables [Member] | Customer Concentration Risk [Member] | Customer One [Member]
Product Information [Line Items]
Concentration Risk, Percentage			17.00%	12.00%
Account Payables [Member] | Customer Concentration Risk [Member] | Customer Three [Member]
Product Information [Line Items]
Concentration Risk, Percentage			12.00%	12.00%
Account Payables [Member] | Customer Concentration Risk [Member] | Customer Four [Member]
Product Information [Line Items]
Concentration Risk, Percentage			11.00%
Maximum [Member]
Product Information [Line Items]
FDIC insured amount	$ 250,000		$ 250,000
Cost of Sales [Member]
Product Information [Line Items]
Shipping and handling costs	500,000	$ 400,000	1,000,000	$ 800,000
Selling, General and Administrative Expenses [Member]
Product Information [Line Items]
Shipping and handling costs	$ 900,000	$ 600,000	$ 1,600,000	$ 1,200,000

Schedule of Inventory (Details)

Schedule of Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 625	$ 332
Finished goods	936	700
Inventory	$ 1,561	$ 1,032

Schedule of Accrued and Other L

Schedule of Accrued and Other Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
Accrued professional fees	$ 114	$ 242
Accrued interest	748	644
Accrued payroll and bonus	630	738
Settlements – short-term (Nutrablend and 4Excelsior)	2,949	2,735
Accrued expenses - ThermoLife	1,364	1,364
Accrued and other short-term liabilities	1,001	1,201
Accrued and other liabilities	$ 6,806	$ 6,924

Schedule of Interest and Other

Schedule of Interest and Other Expense, Net (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Other Income and Expenses [Abstract]
Interest expense, related party	$ (147)	$ (76)	$ (282)	$ (152)
Interest expense, other	(235)	(175)	(443)	(332)
Interest expense, secured borrowing arrangement	(258)	(383)	(424)	(748)
Foreign currency transaction loss	34	16	32	(18)
Other	105	74	437	167
Total interest and other expense, net	$ (501)	$ (544)	$ (680)	$ (1,083)

Schedule of Supplemental Balanc

Schedule of Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Leases [Abstract]
Assets: Operating	$ 338	$ 474
Current liabilities: Operating	424	381
Non-current liabilities: Operating	119	343
Total lease liabilities	$ 543	$ 724

Schedule of Supplemental Cash F

Schedule of Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Leases [Abstract]
Operating cash flows from operating leases	$ 180	$ 397
Operating cash flows from finance leases		1
Financing cash flows from finance leases		$ 52
The weighted average remaining lease term : Operating leases (in years)	1 year 2 months 12 days	2 years
The weighted average remaining lease term : Finance leases (in years)		1 month 6 days
The weighted average discount rate: Operating leases	18.00%	18.00%
The weighted average discount rate: Finance leases		5.00%

Schedule of Other Long-Term Lia

Schedule of Other Long-Term Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Obligation with Joint and Several Liability Arrangement [Line Items]
Other long-term debt	$ 3,786	$ 5,071
Settlements – long-term (Nutrablend and 4Excelsior) [Member]
Obligation with Joint and Several Liability Arrangement [Line Items]
Other long-term debt	3,143	3,906
Paycheck Protection Program loan [Member]
Obligation with Joint and Several Liability Arrangement [Line Items]
Other long-term debt	643	965
Other [Member]
Obligation with Joint and Several Liability Arrangement [Line Items]
Other long-term debt		$ 200

Debt (Details Narrative)

Debt (Details Narrative) - USD ($)

Jun. 14, 2021

Sep. 25, 2020

May 14, 2020

Apr. 10, 2019

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2021

Jun. 30, 2020

Dec. 31, 2020

Nov. 29, 2020

Oct. 15, 2020

Aug. 21, 2020

Jan. 31, 2016

Debt Instrument [Line Items]

Original principal amount

$ 2,000,000

Debt description

the Company agreed to (i) pay approximately $3.1 million (“Owed Amount”) in monthly payments (“Monthly Payments”) from September 1, 2020 through June 30, 2023 and (ii) issue monthly purchase orders (“Purchase Orders”) at minimum amounts accepted by Nutrablend.

Long term liabilities

$ 100,000

$ 100,000

Other long-term liabilities [Member]

Debt Instrument [Line Items]

Interest Payable

1,000,000

1,000,000

Prestige Capital Corporation [Member]

Debt Instrument [Line Items]

Proceed from loan

$ 1,000,000

Debt instrument term

6 months

Debt instrument, interest rate

15.00%

Accommodation Fees

2.00%

Purchase and Sale Agreement [Member]

Debt Instrument [Line Items]

Original principal amount

5,300,000

5,300,000

$ 7,100,000

$ 12,500,000

Interest rate

80.00%

Remaining interest rate

20.00%

Purchase and Sale Agreement [Member] | Minimum [Member]

Debt Instrument [Line Items]

Disount fee interest rate

0.70%

Purchase and Sale Agreement [Member] | Maximum [Member]

Debt Instrument [Line Items]

Disount fee interest rate

4.00%

Convertible Note [Member]

Debt Instrument [Line Items]

Interest expense related to related party

100,000

$ 100,000

200,000

$ 200,000

Paycheck Protection Program [Member] | Harvest Small Business Finance, LLC [Member]

Debt Instrument [Line Items]

Interest rate

1.00%

Debt description

The Note is expected to mature on May 16, 2025. Payments were due by November 16, 2020 (the “Deferment Period”) and interest was accrued during the Deferment Period.

Maturity date

May 16, 2025

Proceeds from debt

$ 964,910

Mr. Ryan Drexler [Member] | The 2020 Refinanced Convertible Note [Member]

Debt Instrument [Line Items]

Original principal amount

$ 2,871,967

Mr. Ryan Drexler [Member] | Convertible Secured Promissory Note [Member]

Debt Instrument [Line Items]

Original principal amount

$ 2,900,000

Interest rate

12.00%

Conversion price

$ 0.23

Mr. Ryan Drexler [Member] | Convertible Secured Promissory Note [Member] | Payment in Kind (PIK) Note [Member]

Debt Instrument [Line Items]

Conversion price

$ 0.10

Mr. Ryan Drexler [Member] | Related Party Secured Revolving Promissory Note [Member]

Debt Instrument [Line Items]

Original principal amount

2,500,000

2,500,000

$ 3,000,000

Interest rate

12.00%

Interest paid in cash

100,000

100,000

Prestige [Member]

Debt Instrument [Line Items]

Aggregate face amount

18,500,000

14,800,000

32,800,000

26,400,000

Proceeds from related party debt

14,700,000

11,700,000

26,200,000

21,100,000

Fees and interest

$ 14,200,000

$ 12,600,000

$ 28,000,000

$ 22,600,000

Prestige [Member] | Purchase and Sale Agreement [Member]

Debt Instrument [Line Items]

Debt description

On April 10, 2019, the Company and Prestige amended the terms of the agreement. The agreement was extended until April 1, 2020 and automatically renews for one (1) year periods unless either party receives written notice of cancellation from the other, at minimum, thirty (30) days prior to the expiration date thereafter.

Maturity date

Apr. 1, 2020

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)

Sep. 02, 2021

Jul. 07, 2021

May 18, 2021

Apr. 27, 2021

Feb. 25, 2021

Sep. 25, 2020

Feb. 27, 2020

Dec. 04, 2019

Oct. 31, 2019

Jul. 07, 2019

Mar. 18, 2019

Aug. 21, 2018

Jul. 07, 2018

Jul. 28, 2017

Jul. 07, 2017

Apr. 04, 2017

Jul. 20, 2021

Oct. 30, 2021

May 31, 2021

Aug. 31, 2021

Jun. 30, 2021

Feb. 28, 2021

Nov. 30, 2020

Jun. 30, 2020

Jun. 30, 2021

Jun. 30, 2020

Dec. 31, 2018

Dec. 31, 2020

Dec. 16, 2020

Dec. 16, 2019

Loss Contingencies [Line Items]

Paid in installment

$ 3,100,000

Remiitted amount

$ 2,100,000

$ 1,800,000

$ 1,500,000

Debt instrument, description

the Company agreed to (i) pay approximately $3.1 million (“Owed Amount”) in monthly payments (“Monthly Payments”) from September 1, 2020 through June 30, 2023 and (ii) issue monthly purchase orders (“Purchase Orders”) at minimum amounts accepted by Nutrablend.

Debt instrument, face amount

$ 2,000,000

Accrued and other liabilities

$ 6,806,000

$ 6,806,000

$ 6,924,000

Other long-term liabilities

4,012,000

4,012,000

$ 5,071,000

Attorneys' fees and costs

$ 56,000

Taxes and penalties

$ 5,300,000

Tax withholdings

4,400,000

Penalties expense

900,000

Accrued penalties

2,000,000

Failure to deposit penalties

$ 2,000,000

Claims amount

$ 7,300,000

$ 5,300,000

Subsequent Event [Member]

Loss Contingencies [Line Items]

Attorneys' fees and costs

$ 92,942

Three Promissory Notes [Member]

Loss Contingencies [Line Items]

Loan exchange value

$ 18,000,000

ThermoLife [Member]

Loss Contingencies [Line Items]

Accrued expenses

1,800,000

$ 1,600,000

Damage value

$ 900,000

Loss contingency, damages sought, value

1,600,000

Interest expenses

300,000

Attorneys' fees and costs

$ 400,000

Bond posted value

600,000

600,000

Repayment of debt

250,000

Accrued and other liabilities [Member]

Loss Contingencies [Line Items]

Litigation Settlement, Expense

1,100,000

Other long-term liabilities [Member]

Loss Contingencies [Line Items]

Paid in installment

800,000

Litigation Settlement, Expense

2,200,000

Interest expenses

100,000

200,000

Maximum [Member]

Loss Contingencies [Line Items]

Line of credit

$ 3,000,000

Forecast [Member]

Loss Contingencies [Line Items]

Remiitted amount

$ 1,400,000

$ 2,100,000

Forecast [Member] | Minimum [Member]

Loss Contingencies [Line Items]

Remiitted amount

$ 700,000

CANADA

Loss Contingencies [Line Items]

Allegedly unpaid invoices

$ 3,100,000

Settlement Agreement [Member]

Loss Contingencies [Line Items]

Accrued expenses

$ 3,000,000

Payments from advance related party

$ 1,000,000

Paid in installment

$ 1,000,000

$ 1,000,000

Remiitted amount

$ 300,000

Interest and other expense

19,000

$ 19,000

38,000

$ 38,000

Nutrablend Matter [Member]

Loss Contingencies [Line Items]

Paid in installment

700,000

Interest and other expense

100,000

100,000

Purchase order

$ 2,000,000

Accrued and other liabilities

1,100,000

1,100,000

Other long-term liabilities

1,000,000

$ 1,000,000

City Football Group Limited [Member] | Sponsorship Agreement [Member]

Loss Contingencies [Line Items]

Loss contingency dispute resolution description

In August 2016, CFG commenced arbitration in the United Kingdom against the Company, seeking approximately $8.3 million for the Company’s purported breach of the Sponsorship Agreement.

Loss contingency dispute resolution amount

$ 8,300,000

4Excelsior [Member]

Loss Contingencies [Line Items]

Damage value

$ 6,200,000

Loss contingency, damages sought, value

$ 7,800,000

Settlement payable

$ 4,750,000

Settlement periodic payments beginning January 5, 2021

70,000

Settlement periodic payments thereafter

$ 100,000

Interest Rate, Stated Percentage

18.00%

Mr. Drexler [Member]

Loss Contingencies [Line Items]

Interest expenses

22,000

44,000

Personal guaranty

$ 350,000

350,000

Legal fees

$ 12,500

Penalty expense

$ 1,500

ThermoLife International LLC [Member]

Loss Contingencies [Line Items]

Loss contingency, damages sought, value

$ 1,800,000

Interest expenses

$ 300,000

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($)	May 12, 2021	Apr. 05, 2021	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock awards granted, shares			25,000	0	25,000	0
Restricted stock awards granted, value			$ 29,000		$ 29,000
Stock-based compensation expense			0	$ 100,000	0	$ 200,000
Agreement [Member] | Cannata [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense			60,000	0	60,000	0
Options issued to purchase common stock	1,673,994
Options exercise price	$ 1.12
Options exercisable term	10 years
Fair value of options	$ 1,900,000
Options term	7 years 6 months
Annual volatility rate	205.00%
Discount rate	1.34%
Dividend rate	0.00%
Transaction Equity Bonus [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense			$ 200,000	$ 0	$ 200,000	$ 0
Equity bonus, Percentage		2.00%
Fair value of award granted		$ 1,000,000

Schedule of Basic and Diluted N

Schedule of Basic and Diluted Net Income (loss) Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020
Earnings Per Share [Abstract]
Net loss	$ (2,251)	$ 94	$ (253)	$ (60)	$ (2,157)	$ (313)
Weighted average common shares used in computing net loss per share, basic and diluted	33,386,200		32,764,553		33,131,087	32,612,956
Net loss per share, basic and diluted	$ (0.07)		$ (0.01)		$ (0.07)	$ (0.01)

Schedule of Outstanding Potenti

Schedule of Outstanding Potentially Dilutive Securities (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total common stock equivalents	12,544,774	2,663,715	12,544,774	2,663,715
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total common stock equivalents			171,703	171,703
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total common stock equivalents				1,289,378
Unvested Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total common stock equivalents				270,660
Convertible Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total common stock equivalents			12,373,071	931,974

Net Loss per Share (Details Nar

Net Loss per Share (Details Narrative) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Earnings Per Share [Abstract]
Potentially diluted securities	12,544,774	2,663,715	12,544,774	2,663,715

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Income Tax Expense (Benefit)	$ 7,000	$ 22,000	$ 7,000	$ 44,000

Schedule of Revenue, Net by Geo

Schedule of Revenue, Net by Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue, net	$ 14,908	$ 16,993	$ 28,029	$ 33,224
UNITED STATES
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue, net	9,050	13,514	18,562	25,361
International [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue, net	$ 5,858	$ 3,479	$ 9,467	$ 7,863

Schedule of Revenue, Net by Maj

Schedule of Revenue, Net by Major Distribution Channel (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Disaggregation of Revenue [Line Items]
Total	$ 14,908	$ 16,993	$ 28,029	$ 33,224
% of Total	100.00%	100.00%	100.00%	100.00%
Specialty [Member]
Disaggregation of Revenue [Line Items]
Total	$ 9,983	$ 8,933	$ 17,055	$ 16,969
% of Total	67.00%	53.00%	61.00%	51.00%
International [Member]
Disaggregation of Revenue [Line Items]
Total	$ 1,775	$ 3,479	$ 6,148	$ 7,863
% of Total	12.00%	20.00%	22.00%	24.00%
FDM [Member]
Disaggregation of Revenue [Line Items]
Total	$ 3,150	$ 4,581	$ 4,826	$ 8,392
% of Total	21.00%	27.00%	17.00%	25.00%

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	Aug. 13, 2021USD ($)Integer$ / shares	Jul. 26, 2021USD ($)shares	Jun. 14, 2021USD ($)	Jun. 30, 2021$ / shares	Dec. 31, 2020$ / shares	Sep. 25, 2020USD ($)
Subsequent Event [Line Items]
Debt principal amount						$ 2,000,000
Common stock par value | $ / shares				$ 0.001	$ 0.001
Prestige Capital Corporation [Member]
Subsequent Event [Line Items]
Proceeds from Loans			$ 1,000,000
Debt Instrument, Term			6 months
Debt Instrument, Interest Rate During Period			15.00%
Subsequent Event [Member]
Subsequent Event [Line Items]
Accommodation fee percent		1.00%
Stock options | shares		18,750
Subsequent Event [Member] | Prestige Capital Corporation [Member]
Subsequent Event [Line Items]
Proceeds from Loans		$ 1,000,000
Debt Instrument, Term		6 months
Debt Instrument, Interest Rate During Period		15.00%
Subsequent Event [Member] | Mr. Ryan Drexler [Member]
Subsequent Event [Line Items]
Debt principal amount	$ 2,457,549
Interest rate	12.00%
Debt conversion, description	At the Company’s option (as determined by its independent directors), the Company may repay up to one sixth of any interest payment by either adding such amount to the principal amount of the August 2021 Convertible Note or by converting such interest amount into an equivalent amount of the Company’s common stock, $0.001 par value per share (the “Common Stock”).
Common stock par value | $ / shares	$ 0.001
Maturity date	Jul. 14, 2022
Subsequent Event [Member] | Mr. Ryan Drexler [Member] | Minimum [Member]
Subsequent Event [Line Items]
Debt Instrument, Convertible, Threshold Trading Days | Integer	15
Subsequent Event [Member] | Mr. Ryan Drexler [Member] | Maximum [Member]
Subsequent Event [Line Items]
Debt Instrument, Convertible, Threshold Trading Days | Integer	60